Acquisition Interest Merck's announced acquisition of Harpoon Therapeutics for approximately 680 million signals strong strategic interest from buyers in Harpoon’s TriTAC platform and T cell engager pipeline, presenting a potential sales opportunity for BD teams to engage with Merck on post-acquisition integration, licensing, or collaboration discussions.

Leverage Platform Harpoon’s TriTAC, ProTriTAC and XR technologies offer differentiated immuno-oncology modalities that could align with pharma partners seeking novel constructs to enhance efficacy and safety, presenting partnership or licensing avenues with companies pursuing solid tumor and hematologic targets.

Pipeline Valuation A pipeline milestone and interim data from Phase 1/2 programs such as HPN328 indicate ongoing clinical value; BD teams can position with potential licensees or co-development partners interested in advancing these assets or leveraging Harpoon’s manufacturing and development capabilities.

Financial Readiness High valuation signals and a substantial funding history (255M in funding; revenue around 10-25M) indicate sufficient financial runway for potential collaborators to negotiate joint development or out-licensing deals without immediate financing risk, making engagement attractive.

Talent and Leadership Recent executive hires and leadership appointments (Chief Legal Officer and Chief People Officer) suggest active governance and organizational growth, presenting opportunities to discuss strategic partnerships aligned with Harpoon’s compliance, IP protection, and scalable clinical development capabilities.